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Human hematopoietic prostaglandin synthase, one of the better therapeutic
target enzymes for allergy and inﬂammation, was crystallized with 22 inhibitors
and in three inhibitor-free conditions in microgravity. Most of the space-grown
crystals showed better X-ray diffraction patterns than the terrestrially grown
ones, indicating the advantage of a microgravity environment on protein
crystallization, especially in the case of this protein.
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1. Introduction
Hematopoietic prostaglandin (PG) D synthase (H-PGDS;
EC 5.3.99.2) is a clinically important protein that is widely
distributed in hematopoietic systems, and produces PGD2
from cyclooxygenase-derived PGH2 (Kanaoka & Urade,
2003). PGD2 mediates allergic and inﬂammatory reactions
through two distinct types of receptors: the D-type prostanoid
receptor (DP) and the chemoattractant receptor-homologous
molecule expressed on Th2 cells (CRTH2). Although indo-
methacin and aspirin are known to suppress allergic and
inﬂammatory reactions, they inhibit the production of all
PGs including cytoprotective and anti-inﬂammatory PGs
(Takeuchi et al., 2001; Halter et al., 2001). Therefore, selective
inhibitors of H-PGDS are considered to be more useful
candidates for anti-allergic and anti-inﬂammatory drugs as
they suppress only the signals mediated by DP and CRTH2.
H-PGDS has been crystallized in a microgravity environ-
ment in Japan Aerospace Exploration Agency (JAXA)’s
space experiments several times since 1997 as summarized in
Table 1. Although it was not easy to obtain good crystals in
earlier space experiments, high-quality crystals were obtained
after JAXA improved crystallization technology and
increased the accessibility of space experiments during a
course of high-quality protein crystallization experiments on
the International Space Station (ISS) starting in 2003 (Sato et
al., 2006). Recently, Takahashi et al. (2010) reported that
crystals of H-PGDS in complexes with novel inhibitors, which
were grown in microgravity in 2007, diffracted up to a 1.1 A ˚
resolution at 100 K using SPring-8 synchrotron radiation, one
of the highest resolutions obtained to date for this protein.
These novel inhibitors were derivatives of 4-benzhydryloxy-1-
[3-(1H-tetrazol-5-yl)-propyl]-piperidine (HQL-79) which is an
orally active anti-allergic drug and speciﬁcally inhibits the
biological activity of H-PGDS (Aritake et al., 2006). More-
over, the novel inhibitors had more than 100 times lower
inhibitory concentrations (IC50) than HQL-79, so they are
expected to be candidates for novel drug design.
In this report we show more crystallization results of H-
PGDS in four recent space experiments performed from 2007
to 2009, and indicate that microgravity positively affects the
solution environment improving the quality of the crystals of
this protein.
2. Materials and methods
2.1. Microgravity experiments
H-PGDS was crystallized at 293 K inside the Russian TBU
incubator on board the Russian Service Module on the ISS for
12, 11 and 10 weeks in JAXA-NGCF#1, #2 and #3, respec-
tively, and inside the Protein Crystallization Research Facility
on board the Japanese Experiment Module ‘Kibo’ on the ISS
for 12 weeks in JAXA PCG#1 as shown in Table 1.
2.2. Protein expression, purification and crystallization
Human H-PGDS was expressed and puriﬁed as previously
described (Aritake et al., 2006; Takahashi et al., 2010). The
crystallization conditions were as follows: a protein solution
contained 4.0 mg ml
1 protein with or without 0.5 mM inhi-
bitor in 150 mM sodium chloride, 15% PEG 6000, 5 mM
dithiothreitol, 5 mM glutathione, 1% dioxane, 0.5 mM
magnesium chloride and 20 mM Tris-HCl pH 8.0, and a
precipitant solution contained 30% PEG 6000, 10 mMdithiothreitol, 10 mM glutathione, 1% dioxane and 1 mM
magnesium chloride in 50 mM Tris-HCl pH 8.4. For other
inhibitor-free conditions the divalent metal ion, magnesium
chloride, was replaced by calcium chloride or a chelating agent
EDTA.
For crystallization, JAXA adopted a gel-tube method
for microgravity experiments, which modiﬁed the original
counter-diffusion method introduced by Garcı ´a-Ruiz &
Moreno (1994) (Garcı ´a-Ruiz, 2003; Ng et al., 2003; Tanaka et
al., 2004a; Gonzalez-Ramirez et al., 2008; Ota ´lora et al., 2009).
Assembly of a crystallization device and a micro-seeding
technique were described previously (Takahashi et al., 2010).
Brieﬂy, 8 ml of the protein solution was put in each glass
capillary (47 mm length, 0.5 mm diameter) to a length of
40 mm. A 6 mm piece of plastic tubing was attached to the end
of the capillary, which contained 1% polymerized agarose gel
pre-soaked in 15% PEG 6000, 10 mM dithiothreitol, 10 mM
glutathione, 2% dioxane, 1 mM magnesium chloride (calcium
chloride or EDTA) and 50 mM Tris-HCl pH 8.4. The top of
the capillary was sealed with clay and epoxy adhesive. The
agarose end of the capillary was placed in a tube which
contained the precipitant solution. Each protein sample was
loaded into three capillaries. A total of 22 kinds of inhibitors
of H-PGDS were co-crystallized. The formulae of the inhibi-
tors are proprietary information. Crystallization conditions
were ﬁxed to start crystallizing after the samples arrived in the
microgravity environment. The same crystallization condition
was applied to the terrestrial experiment as the control.
2.3. Data collection and analysis
Diffraction data were collected from a single crystal at
100 K using an X-ray wavelength of 0.85 A ˚ on the BL41XU
beamline at SPring-8, Harima, Japan, with an ADSC315
detector system, or using an X-ray wavelength of 1.0 A ˚ on the
X06SA beamline at the Paul Scherrer Institute (PSI), Villigen-
PSI, Switzerland, with a MAR225 detector system. The
methods of crystal extraction from capillaries and harvesting
crystals were previously described (Tanaka et al., 2004a, 2007).
Prior to data collection, a crystal was scooped with a nylon
loop, brieﬂy soaked in an artiﬁcial mother liquor supple-
mented with 15% glycerol as a cryoprotectant, and plunged
into a nitrogen-gas stream at 100 K. The diffraction images
collected at SPring-8 were integrated and scaled using the
programs DENZO and SCALEPACK from HKL2000
(Otwinowski & Minor, 1997), and the images collected at PSI
using XDS (Kabsch, 1993). X-ray diffraction data for each
sample were obtained from two to three crystals with
approximate dimensions of 0.03  0.1  0.05 mm. A summary
of the best data is listed in Table 2. Data sets were collected up
to the resolution range I/(I)>2a n dRmerge < 50%.
3. Results and discussion
3.1. Crystallization and X-ray diffraction analysis
The sizes of the crystals grown in space were about the same
or sometimes signiﬁcantly larger than those grown on the
ground and several times larger than those grown with the
vapour-diffusion method. All the crystals chosen for diffrac-
tion data collection were grown in the upper part of the
capillaries where crystals of better quality tend to grow
(Lopez-Jaramillo et al., 2003), and those were of good quality
as judged by a visual inspection.
As shown in Table 2, H-PGDS was crystallized under 25
different conditions in total, both in space and on the ground:
22 with an inhibitor and three without an inhibitor but with a
different divalent metal ion (Mg
2+: sample ID S/G6; Ca
2+:
sample ID S/G7) or a chelating agent (EDTA: sample ID
S/G8).
Comparisons of the quality of space-grown and ground-
grown crystals are invalid if X-ray diffraction experiments are
not performed or if the same beamline is not used for both
space-grown and ground-grown crystals of the same sample.
Therefore, we must exclude S/G7, S/G12, S/G13 and S/G15–19
because X-ray diffraction experiments were, unfortunately,
not performed owing to the unavailability of beam time, and
S/G2 because X-ray diffraction data were collected at SLS
diffraction structural biology
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Table 1
H-PGDS crystallization experiments in space conducted by JAXA.
CVDA: commercial vapour-diffusion apparatus. HDPCG: high-density protein crystal growth. GCB: Granada crystallization box. JCB: JAXA crystallization box.
Flight # Duration
Crystallization
device Launch/retrieval
Crystallization
condition
number Details
STS-84 10 days, May 1997 CVDA Space shuttle Atlantis 1 Space-grown and ground-grown crystals
diffracted to 3.0 A ˚ and 2.7 A ˚ ; mosaicity
was 0.6 and 0.3, respectively
STS-107 16 days, January–February 2003 HDPCG Space shuttle Columbia 1 No results owing to a tragic mission failure
NASDA-GCF#1 13 weeks, February–May 2003 GCB Progress 10P/Soyuz 5S 1 Precipitate occurred both in space and on
the ground
NASDA-GCF#2 9 weeks, August–October 2003 GCB Progress 12P/Soyuz 6S 3 Precipitate occurred both in space and on
the ground
NASDA-GCF#3 13 weeks, January–April 2004 GCB Progress 13P/Soyuz 7S 2 Space-grown crystal diffracted to 1.3 A ˚ for
the ﬁrst time (mosaicity 0.362)
JAXA-NGCF#1 12 weeks, January–April 2007 JCB Progress 24P/Soyuz 13S 8 See Table 2
JAXA-NGCF#2 11 weeks, August–October 2007 JCB Progress 26P/Soyuz 14S 4 See Table 2
JAXA-NGCF#3 10 weeks, February–April 2008 JCB Progress 28P/Soyuz 15S 7 See Table 2
JAXA PCG#1 12 weeks, July–October 2009 JCB Progress 34P/Soyuz 18S 8 See Table 2beamline X06SA for only the space-grown crystals for this
condition.
In the case of S/G20–22, X-ray diffraction experiments were
not performed both for space-grown and ground-grown crys-
tals owing to the poor shape of the crystals. In the case of S/
G11, no crystallization was observed both for space-grown and
ground-grown crystals.
Therefore, there are 12 samples that were valid for
comparison, as shown in bold face in Table 2. Among these
samples, S/G24 and S/G25 showed improvement of crystal-
lizability in space-grown crystals, which was indicated by the
size and the shape of the crystals, respectively. The micro-
gravity environment improved the maximum resolution and
mosaicity in S/G1, S/G3, S/G4, S/G6, S/G8–10 and S/G14. In
the case of S/G5, the microgravity environment improved the
maximum resolution but not the mosaicity. For S/G23, the
microgravity environment did not improve the maximum
resolution but did improve mosaicity.
3.2. Microgravity effects
The microgravity environment deﬁnitely had a positive
effect on the growth of high-quality H-PGDS crystals as
shown by the better results of space-grown crystals of 12
comparable samples. When comparing two to three crystals of
each sample, a superior quality improvement of space-grown
crystals was mostly observed, although there were some
deviations in the X-ray diffraction data quality of crystals
grown both in space and on the ground. The absence of
convective ﬂuid motion in microgravity is known to decrease
protein concentration around the growing crystal, forming
a protein depletion zone (PDZ) (Ota ´lora et al., 2001). The
slower growth of crystals in the PDZ is thought to be prefer-
able for a better-ordered intermolecular arrangement in a
crystal, which may be one of the reasons for the improved
quality of space-grown crystals. Impurity incorporation also
affects the intermolecular order (Dold et al., 2006). An
impurity depletion zone (IDZ) can also be expected to form
around the growing crystal (Chernov, 1998), which may reduce
the incorporation of impurity molecules into the crystals in
space (Thomas & Chernov, 2001).
Tanaka et al. (2004b) previously reported that D/ (diffu-
sive coefﬁcient of a protein molecule/kinetic constant for
crystal growth), which represents the ratio between ‘the
molecule transportation to a surface of a crystal’ versus ‘its
uptake into a crystal’ (Chernov, 1998), can be used as an index
diffraction structural biology
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Table 2
Summary of the X-ray diffraction experiments of H-PGDS crystals.
The best data of the X-ray diffraction experiments on two to three crystals for each complex of H-PGDS with compound are shown. Data sets were collected up to
the resolution range I/(I)>2 and Rmerge<50%.Data shownin boldfacewere usedfordata comparisonbetweenspace-grownandground-grown crystals(seetext
for details). All of the data except S2 were collected at SPring-8 BL41XU beamline.
Space experiment Ground experiment
Sample
ID
Maximum
resolution
(visual
observation)
(A ˚ )
Maximum
resolution
(data set)
(A ˚ ) Mosaicity
Space
group
Sample
ID
Maximum
resolution
(visual
observation)
(A ˚ )
Maximum
resolution
(data set)
(A ˚ ) Mosaicity
Space
group Flight #
S1 <1.10 1.10 0.623 P1 G1 1.50 1.80 0.812 P1 JAXA-NGCF#1
S2† 1.20 1.20 0.178 P1 G2 2.00 –‡ 1.736 P1 JAXA-NGCF#1
S3 1.12 1.14 0.560 P1 G3 2.00 –† 3.386 P1 JAXA-NGCF#1
S4 1.90 1.90 1.334 P1 G4 2.00 2.00 1.528 P1 JAXA-NGCF#1
S5 1.30 1.30 1.707 P1 G5 1.50 1.50 1.281 P1 JAXA-NGCF#1 and #2
S6§ 1.50 1.50 0.36–0.54 P21 G6§ 1.70 1.75 1.05–2.47 P21 JAXA-NGCF#1 and #2
S7§ 1.40 1.40 1.329 P1G 7 § – } JAXA–NGCF#1
S8§ 1.26 1.30 1.109 P1 G8§ 2.50 2.50 1.305 P1 JAXA-NGCF#1
S9 1.40 1.78 0.43–1.48 P1 G9 2.00 –†† JAXA-NGCF#2
S10 1.30 1.50 0.66–1.03 P1 G10 2.10 –†† JAXA-NGCF#2
S11 –‡‡ G11 –‡‡ JAXA-NGCF#3
S12 1.80 1.90 0.60–1.12 P21 G12 –} JAXA-NGCF#3
S13 1.47 1.48 0.63–1.43 P1G 1 3 – } JAXA-NGCF#3
S14 1.40 1.68 0.61–1.01 P21 G14 1.66 1.70 0.61–4.48 P1 JAXA-NGCF#3
S15 –} G15 –} JAXA-NGCF#3
S16 –} G16 –} JAXA-NGCF#3
S17 1.80 1.80 0.35–0.93 P21 G17 –} JAXA-NGCF#3
S18 1.80 –‡ – I41 G18 –} JAXA PCG#1
S19 1.10 1.32 0.25–0.42 P1G 1 9 – } JAXA PCG#1
S20 –§§ G20 –§§ JAXA PCG#1
S21 –§§ G21 –§§ JAXA PCG#1
S22 –§§ G22 –§§ JAXA PCG#1
S23 1.45 1.50 0.34–0.65 P1 G23 1.35 1.50 0.48–1.53 P1 JAXA PCG#1
S24 1.75 –†† 0.940 P1 G24 –†† JAXA PCG#1
S25 1.76 1.78 0.40–0.74 P21 G25 –§§ JAXA PCG#1
† X-ray diffraction data set was collected at SLS beamline X06SA. ‡ X-ray diffraction data set was not collected because of high mosaicity. § Inhibitor-free condition. } Beam
time was not available. †† X-ray diffraction data set was not collected because the crystals were too small. ‡‡ No crystallization was observed. §§ X-ray diffraction experiment was
not performed because the crystal was a cluster and not suitable for diffraction experiment.of both PDZ and IDZ. In short, if D/ is less than the size of
the growing crystal it means that depletion zones would be
formed around the crystal in a diffusion-controlled environ-
ment. Since the measurement of D and  is not easy to
calculate for most of the proteins, we applied a simpliﬁed
method of estimating those values of H-PGDS, using the
molecular weight of the protein and the precipitant, the
concentration of the crystallization solution, the time to grow
to half of the ﬁnal crystal size, and the concentration and the
solubility of the protein (Tanaka et al., 2004b). We calculated
that D/ of H-PGDS is 0.39 mm which is almost the
comparative order to the crystal size. This may indicate that
the H-PGDS crystals obtained in the space experiments were
grown surrounded by a PDZ and IDZ, which may result in
growing high-quality crystals in microgravity. Although the
reason for the improvement of crystal quality in microgravity
still remains a matter of speculation, H-PGDS is likely to be a
better quality protein crystallized in microgravity. Using these
high-quality X-ray diffraction data sets,a design for novel drug
candidates is now underway.
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